Web Research

Web Research — Centene Corporation (CNC)

The Bottom Line from the Web

The internet's verdict on Centene since the July 2025 guidance pull is sharply different from the company's own framing: an active securities-fraud class action (Hagens Berman, filed July 2025) alleges management knew the 2025 Marketplace book was underpriced before saying so publicly, and analyst sentiment has converged on a "Hold" with a mean target near $41 — barely above the current ~$38 share price after a 60%+ peak-to-trough draw-down. Management's $3.00+ 2026 adjusted-EPS guide is now the entire bull case, anchored on a 95%-repriced Marketplace book and a Medicaid HBR that fell from 94.9% (Q2 2025) to 93.0% (Q4 2025); the bear case is OBBBA's Medicaid work-requirement and state-directed-payment phase-down hitting in 2027–2028 just as EAPTC expiration shrinks Marketplace by an Urban Institute–estimated 4.8 million lives.

What Matters Most

1. Active securities-fraud class action — discovery underway

A securities class action led by Hagens Berman was filed in July 2025 on behalf of investors who bought CNC between December 2024 and July 1, 2025, alleging management concealed Marketplace morbidity and Medicaid cost trends before pulling 2025 guidance. The complaint frames the July 1 disclosure as "$11 billion of shareholder value wiped out in a day." A second-related action is being maintained by Kessler Topaz. As of April 2026 the case is in pre-trial discovery; an Apex notice gives claimants until June 8, 2026 to file. (Hagens Berman, Kessler Topaz case page, Apex notice)

2. The 2026 EPS guide is the entire bull case — and analysts don't fully buy it

On February 6, 2026 management guided 2026 adjusted diluted EPS to above $3.00 on revenue of $186.5–$190.5B with HBR of 90.9–91.7%. Q4 2025 adjusted EPS was a $1.19 loss (slight beat vs. consensus loss of $1.22). The Street's consensus rating is Hold (3 buys, 2 outperforms, 13 holds among 17 analysts on stockanalysis.com), with a mean price target of roughly $40.56–$43.18 depending on source. The target spread of $28 to $70 reflects a binary read on whether Medicaid HBR holds the 93.0–93.7% line through mid-year rate cycles. (Centene press release, stockanalysis.com, TIKR analysis)

3. Marketplace pricing reset — the most important forward indicator

Management has repriced >95% of the 2026 Marketplace book with average rate increases in the mid-30s percent to absorb baseline morbidity, trend, and EAPTC expiration. Ambetter membership is expected to fall from ~5.0M (December 2025) to ~3.5M at end of Q1 2026 as a deliberate self-cull of unprofitable lives. Management is targeting a Marketplace pretax margin recovery from -1% to roughly +4% in 2026, within a stated 5%–7.5% margin range. (Q4 2025 earnings call summary, Defense World, Globe and Mail)

4. OBBBA Medicaid step-down — the 2027–2028 cliff

The One Big Beautiful Bill Act, signed July 4, 2025 (Public Law 119-21), is the dominant medium-term overhang. Key dates:

• December 31, 2026 — states must implement Medicaid work-reporting requirements and notify enrollees (Center for American Progress)
• January 1, 2028 — state-directed payment caps begin phasing down 10 percentage points per year toward 100% of Medicare for expansion states (Greenbaum Law)
• Annual — provider-tax safe harbor declines 0.5pp per year from 6% (Paragon Institute)
• October 2028 or 2029 — implementation can be delayed for states with the highest error rates in October 2027

Independent forecast: Urban Institute estimates 4.8 million people will lose Marketplace coverage in 2026 if Enhanced Advance Premium Tax Credits expire — directly hits Ambetter's addressable market. (Urban Institute)

5. Goodwill impairment composition — admission of overpaid M&A

The Q3 2025 $6.7B non-cash goodwill impairment was triggered by the company's quantitative test after market conditions deteriorated in July 2025. A subsequent $513M impairment on Magellan Health ($389M after-tax) was recorded in Q4 2025 in connection with a December 2025 definitive agreement to divest the remaining Magellan businesses. Combined with the WellCare and Magellan acquisition history, the writedowns effectively concede that ~$7.2B of paid M&A premium will not be recovered. (Insurance Business, 10-K filing summary)

6. Industry context: Centene's MLR miss is partly cyclical, partly company-specific

Molina Healthcare's February 5, 2026 results delivered an even more punishing reset: 2026 adjusted EPS guidance of $5.00 versus $13.76 consensus, with a 2025 medical cost ratio of 91.7%. Humana, by contrast, raised 2025 guidance in Q3 on better Medicare Advantage cost control. The cross-read: ACA Marketplace morbidity is an industry-wide event, but Medicaid trend pressure is not uniform — Humana's outperformance suggests the Medicaid weakness is partially Centene-specific (geographic concentration in Florida/New York carve-ins). (Healthcare Dive on Molina, Healthcare Dive on Humana)

7. PBM legacy: 20+ states settled, two large holdouts remain

Centene has paid more than $1 billion across 20+ state Medicaid PBM-overcharge settlements since 2021. Florida and Georgia have not settled as of March 2025 — both states hired the same outside firm (Liston & Deas) but the Florida case has gone publicly silent and Georgia has "taken disproportionately long." The Georgia Medicaid plan (Peach State Health Plan) lost its 2024 reprocurement bid, which may be related. The residual liability tail is in the low-to-mid hundreds of millions, but a fresh state action could re-open the issue. (KFF Health News, HealthLeaders Media)

8. CEO insider buying — small relative to total comp, paused in 2026

Sarah London bought $1.9M at $62.60 (March 2023) and $250,313 at ~$58 (November 2024). No 2025 or 2026 open-market purchases are recorded as of Form 4 data through April 2026 — only tax-withholding for vesting RSUs. London's total 2024 compensation was reported as $19.5M (per simplywall.st) with 7.6% salary and 92.4% equity; she directly owns 0.06% of shares (~$12.5M at current prices). The absence of a follow-on buy after the August 2025 stock collapse is the more telling data point: a CEO with conviction on the recovery would typically have stepped in. (Form 4 history, secform4.com, Yahoo Finance, simplywall.st management profile)

9. Capital position remains a strength

Despite the 2025 GAAP loss, Centene generated $5.1B of operating cash flow in 2025 and ended the year with $38.8B in cash, investments and restricted deposits. The credit facility was renewed and doubled to $4 billion in Q1 2025 (zero drawn as of June 30). On March 25, 2026 the company executed a $1B partial redemption of its 4.25% notes. Buyback yield is reported at 5.85%. Moody's last rated senior debt at Ba1 (2021) and there were Becker's Payer Issues reports of "potential junk rating" risk in July 2025, but no actual downgrade has been reported. (Q4 2025 earnings call transcript via Investing.com, TIKR)

10. New senior hires reshape the C-suite

On April 7, 2026 Centene announced two new Group President roles. Daniel Finke joined from CEO of Convey Health Solutions (where he served from January 2024); previously president of Aetna (2014–2023) and EVP at EmblemHealth, with 30+ years' health-insurance experience. The hire is a credible operator addition, but it also signals the existing reporting structure was inadequate. (DistilINFO, Becker's Payer Issues)

Recent News Timeline

Key Numbers from the Web

What the Specialists Asked

Insider Spotlight

Sarah London (CEO since March 2022)

CEO and Director of Centene; age ~43; previously vice chair of the board. Total 2024 reported compensation $19.5M (7.6% salary, 92.4% equity). Direct ownership 0.06% (~$12.5M). Open-market purchases: 30,300 shares at $62.60 (March 2023, $1.9M) and 4,277 shares at $58.50 (November 2024, $250K). No 2025 or 2026 open-market purchases. Holdings approximately 667,229 shares as of November 2024 disclosure.

Kenneth Burdick (Director)

Joined the board following the WellCare merger (2020). Acquired 556 CNC shares on June 30, 2025 (small director grant, total holding ~367k). Currently transitioning from Executive Chair to non-executive Chair of LifeStance Health (effective March 16, 2026). Annual LifeStance compensation as non-executive chair: $200K cash retainer + ~$500K RSUs.

Frederick H. Eppinger (Director)

Received a grant of 1,690 shares of common stock per March 2026 Form 4. Standard director equity refresh.

Katie Casso, Drew Asher (Officer-level)

Recent Form 4 activity is exclusively tax-share withholding for vested RSUs — no open-market activity in 2025–2026.

Industry Context

Managed-care 2026 setup is bifurcated

ACA Marketplace is universally repricing higher and shrinking; Medicaid is mid-cycle in rate-acuity catch-up; Medicare Advantage is benefiting from a CMS-finalized 2027 rate increase of +2.48% (~$13B more in payments). The 2026 Star Ratings overhaul (CMS reverted to a more generous bonus system, cut nearly a dozen metrics) directly benefits Centene's Wellcare, where 60% of members are now in 3.5+ Star plans (up from 55% prior cycle). (Healthcare Dive on Star Ratings, CMS press release)

Peer earnings cross-read

EAPTC expiration is the single biggest 2026 macro risk

If Enhanced Advance Premium Tax Credits expire as scheduled, the Urban Institute estimates 4.8M Marketplace lives lost in 2026 — proportionate impact on Ambetter's footprint. Open Enrollment for plan year 2027 will also be shorter (Nov 1, 2026 onward) per OBBBA. This is the macro variable that could either validate management's ~3.5M Q1 2026 Ambetter target or push it lower. (Urban Institute)